NCT01958060View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers

PHASE1TerminatedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Healthy
Interventions
DRUG

BI 1034020

intravenous part

DRUG

Placebo to BI 1034020

intravenous part

Trial Locations (2)

Unknown

1312.1.1 Boehringer Ingelheim Investigational Site, Biberach

1312.1.2 Boehringer Ingelheim Investigational Site, Ingelheim

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01958060 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers | Biotech Hunter | Biotech Hunter